10-Q: Trevi Therapeutics Reports Q1 2025 Financial Results, Highlights Progress in Chronic Cough Programs

Trevi Therapeutics reports its Q1 2025 financial results, showcasing ongoing clinical trial progress for Haduvio in treating chronic cough related to IPF, non-IPF ILD, and RCC.

Summary

• Trevi Therapeutics reported a net loss of $10.34 million for the three months ended March 31, 2025, compared to a net loss of $10.90 million for the same period in 2024.
• Research and development expenses decreased to $7.81 million from $8.80 million year-over-year, primarily due to decreased clinical development expenses for the HAP study.
• General and administrative expenses increased to $3.66 million from $3.10 million year-over-year, driven by higher stock-based compensation and personnel-related expenses.
• Cash, cash equivalents, and marketable securities totaled $103.3 million as of March 31, 2025.
• The company believes its current resources will fund operations for at least 12 months from the date of the financial statements.
• Trevi completed enrollment in the Phase 2b CORAL clinical trial in February 2025 and expects to announce topline results in the second quarter of 2025.
• Positive topline data was announced from the Phase 2a RIVER trial of Haduvio in patients with RCC, showing a statistically significant reduction in 24-hour cough frequency.
• The company is designing its next trial of Haduvio in patients with RCC to determine doses and further characterize safety.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is still operating at a loss, it has made progress in its clinical trials and has sufficient cash to fund operations for the next 12 months. The company is also planning a Phase 3 program for Haduvio for chronic cough in patients with IPF in the first half of 2026, pending Phase 2b CORAL clinical trial results.

Positives

• Trevi Therapeutics has $103.3 million in cash, cash equivalents and marketable securities.
• The Phase 2a RIVER trial demonstrated a statistically significant reduction in cough frequency for RCC patients.
• The company completed enrollment in the Phase 2b CORAL clinical trial.
• The company is planning a Phase 3 program for Haduvio for chronic cough in patients with IPF in the first half of 2026, pending Phase 2b CORAL clinical trial results.

Negatives

• Trevi Therapeutics reported a net loss of $10.34 million for Q1 2025.
• The company has an accumulated deficit of $297.4 million as of March 31, 2025.
• The company has not generated any revenue from product sales.

Risks

• The company is dependent on the successful development and commercialization of Haduvio.
• Clinical trials may not demonstrate the safety and efficacy of Haduvio.
• The regulatory approval process is expensive, time-consuming, and uncertain.
• The company will need substantial additional funding, and if it is unable to raise sufficient capital, it could be forced to delay, reduce, or abandon its product development programs or commercialization efforts.
• The company faces competition, which may result in others developing or commercializing products before or more successfully than it does.

Future Outlook

Trevi Therapeutics expects to announce topline results from the Phase 2b CORAL clinical trial in the second quarter of 2025 and, subject to the results, plans to initiate a Phase 3 program for Haduvio for chronic cough in patients with IPF in the first half of 2026. The company believes its existing cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditure requirements into the fourth quarter of 2026.

Management Comments

• The company believes that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of issuance of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q.

Industry Context

Trevi Therapeutics is operating in a competitive biopharmaceutical landscape, focusing on chronic cough treatments where there is a high unmet medical need, particularly in IPF, non-IPF ILD, and RCC. The company faces competition from other pharmaceutical companies developing treatments for these conditions.

Comparison to Industry Standards

• The report mentions competitors such as Nerre Therapeutics (orvepitant), Melius Pharma (ME-015), Boehringer Ingelheim (BI 1839100), and GSK plc (camlipixant) who are developing treatments for similar indications.
• Merck's gefapixant, approved in Europe, Switzerland, and Japan for refractory or unexplained chronic cough, serves as a benchmark in the RCC space, although its FDA application was withdrawn.
• The company's approach with Haduvio, an oral extended-release formulation of nalbuphine, is differentiated from existing injectable nalbuphine products and aims to address the limitations of current cough treatments.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's ability to fund operations will impact job security and compensation.
• Patients: The company's clinical trial progress will impact the availability of new treatments for chronic cough.
• Suppliers: The company's financial performance will impact its ability to pay suppliers.

Next Steps

• Announce topline results from the Phase 2b CORAL clinical trial in the second quarter of 2025.
• Design the next trial of Haduvio in patients with RCC.
• Potentially initiate a Phase 3 program for Haduvio for chronic cough in patients with IPF in the first half of 2026, pending Phase 2b CORAL clinical trial results.

Key Dates

Keywords

Haduvio, chronic cough, idiopathic pulmonary fibrosis, IPF, refractory chronic cough, RCC, non-IPF ILD, clinical trials, nalbuphine ER, Trevi Therapeutics, financial results